Nephrotoxicity in the setting of invasive fungal diseases

Mycoses

Volumn 51, Issue SUPPL. 1, 2008, Pages 25-30

  Ullmann, Andrew J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Amphotericin B; Creatinine; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; TACROLIMUS;

ARTICLE; ASPERGILLOSIS; COST OF ILLNESS; CREATININE BLOOD LEVEL; DRUG COST; DRUG EFFECT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MONEY; MORTALITY; MYCOSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY DISEASES; LENGTH OF STAY; MYCOSES; TREATMENT OUTCOME;

EID: 43549123527     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01525.x     Document Type: Article

References (38)

1. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis Dec 1999 29 : 1402 7.
2. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002 35 : 359 66.
3. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998 27 : 1406 12.
4. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 15.
5. Bates DW, Su L, Yu DT et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001 60 : 1452 9.
6. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007 369 : 1519 27.
7. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007 44 : 1289 97.
8. Ullmann AJ, Sanz MA, Tramarin A et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006 43 : e29 38.
9. Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 1998 103 : 198 204.
10. Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001 21 : 1107 14.
11. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 : 1391 402.
12. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 9.
13. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000 31 : 1155 63.
14. White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998 27 : 296 302.
15. Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002 49 (Suppl. 1 81 86.
16. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997 98 : 711 8.
17. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999 43 : 267 71.
18. Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002 35 : e120 7.
19. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 26 : 1383 96.
20. Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006 50 : 658 66.
21. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001 32 : 686 93.
22. Bardi E, Bobok I, Olah AV, Olah E, Kappelmayer J, Kiss C. Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatr Nephrol 2004 19 : 1145 7.
23. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002 49 (Suppl. 1 37 41.
24. Bell NH, Andriole VT, Sabesin SM, Utz JP. On the nephrotoxicity of amphotericin B in man. Am J Med 1962 33 : 64 69.
25. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002 132 : 316 20.
26. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983 35 : 211 5.
27. Churchill DN, Seely J. Nephrotoxicity associated with combined gentamicin-amphotericin B therapy. Nephron 1977 19 : 176 81.
28. Stein RS, Albridge K, Lenox RK, Ray W, Flexner JM. Nephrotoxicity in leukemic patients receiving empirical amphotericin B and aminoglycosides. South Med J 1988 81 : 1095 9.
29. Branch RA, Jackson EK, Jacqz E et al. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr 1987 65 : 500 6.
30. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988 148 : 2389 94.
31. Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci 1989 298 : 299 304.
32. Girmenia C, Gentile G, Micozzi A, Martino P. Nephrotoxicity of amphotericin B desoxycholate. Clin Infect Dis 2001 33 : 915 6.
33. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001 322 : 579 82.
34. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003 36 : 943 51.
35. Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000 18 : 2476 83.
36. Kaskel P, Tuschy S, Wagner A et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2008 87 : 311 9.
37. Pathak A, Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis 1998 26 : 334 8.
38. Klibanov OM, Raasch RH, Rublein JC. Changes in renal function after changes in antifungal drug therapy. Am J Health Syst Pharm 2004 61 : 50 53.